• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当前新冠病毒疫苗策略的成功与严重急性呼吸综合征冠状病毒2刺突蛋白受体结合域(RBD)的表位拓扑结构对比:一项用于指导未来疫苗设计的RBD拓扑结构计算研究

Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design.

作者信息

Addala Santhinissi, Vissapragada Madhuri, Aggunna Madhumita, Mukala Niharikha, Lanka Manisha, Gampa Shyamkumar, Sodasani Manikanta, Chintalapati Jahnavi, Kamidi Akhila, Veeranna Ravindra P, Yedidi Ravikiran S

机构信息

Stem Cell Biology Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.

Synthetic Biology Branch, Department of Intramural Research Core, The Center for Advanced-Applied Biological Sciences & Entrepreneurship (TCABS-E), Visakhapatnam 530016, India.

出版信息

Vaccines (Basel). 2022 May 25;10(6):841. doi: 10.3390/vaccines10060841.

DOI:10.3390/vaccines10060841
PMID:35746449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9228374/
Abstract

Coronavirus disease-2019 (COVID-19) is a pandemic with a high morbidity rate occurring over recent years. COVID-19 is caused by the severe acute respiratory syndrome causing coronavirus type-2 (SARS-CoV-2). COVID-19 not only challenged mankind but also gave scope to the evolution of various vaccine design technologies. Although these vaccines protected and saved many lives, with the emerging viral strains, some of the strains may pose a threat to the currently existing vaccine design that is primarily based on the wild type spike protein of SARS-CoV-2. To evaluate the risk involved from such mutant viral strains, we performed a systematic in silico amino acid substitution of critical residues in the receptor binding domain (RBD) of the spike protein. Our molecular modeling analysis revealed significant topological changes in the RBD of spike protein suggesting that they could potentially contribute to the loss of antigen specificity for the currently existing therapeutic antibodies/vaccines, thus posing a challenge to the current vaccine strategies that are based on wild type viral spike protein epitopes. The structural deviations discussed in this article should be considered carefully in the future vaccine design.

摘要

2019冠状病毒病(COVID-19)是近年来发病率很高的一种大流行病。COVID-19由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起。COVID-19不仅给人类带来了挑战,也为各种疫苗设计技术的发展提供了空间。尽管这些疫苗保护并拯救了许多生命,但随着新出现的病毒株,其中一些毒株可能会对目前主要基于SARS-CoV-2野生型刺突蛋白的疫苗设计构成威胁。为了评估此类突变病毒株带来的风险,我们对刺突蛋白受体结合域(RBD)中的关键残基进行了系统的计算机模拟氨基酸替换。我们的分子建模分析显示,刺突蛋白的RBD有显著的拓扑变化,这表明它们可能会导致现有治疗性抗体/疫苗的抗原特异性丧失,从而对目前基于野生型病毒刺突蛋白表位的疫苗策略构成挑战。本文讨论的结构偏差在未来疫苗设计中应予以仔细考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/449cdfde9047/vaccines-10-00841-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/1f9101205d73/vaccines-10-00841-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/9b84fd1559d2/vaccines-10-00841-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/db35a250015c/vaccines-10-00841-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/760ee9056c71/vaccines-10-00841-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/b43d0875951c/vaccines-10-00841-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/449cdfde9047/vaccines-10-00841-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/1f9101205d73/vaccines-10-00841-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/9b84fd1559d2/vaccines-10-00841-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/db35a250015c/vaccines-10-00841-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/760ee9056c71/vaccines-10-00841-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/b43d0875951c/vaccines-10-00841-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/465e/9228374/449cdfde9047/vaccines-10-00841-g006.jpg

相似文献

1
Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design.当前新冠病毒疫苗策略的成功与严重急性呼吸综合征冠状病毒2刺突蛋白受体结合域(RBD)的表位拓扑结构对比:一项用于指导未来疫苗设计的RBD拓扑结构计算研究
Vaccines (Basel). 2022 May 25;10(6):841. doi: 10.3390/vaccines10060841.
2
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
3
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
4
An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.一种工程化受体结合域可提高多价SARS-CoV-2疫苗的免疫原性。
mBio. 2021 May 11;12(3):e00930-21. doi: 10.1128/mBio.00930-21.
5
Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches.针对 SARS-CoV-2 的多表位疫苗:应用免疫信息学和分子动力学模拟方法。
J Biomol Struct Dyn. 2022 Apr;40(7):2917-2933. doi: 10.1080/07391102.2020.1844060. Epub 2020 Nov 9.
6
A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation.一种基于 SARS-CoV-2 刺突糖蛋白潜在免疫原性片段构建的疫苗:一种计算近似。
J Immunol Methods. 2022 Mar;502:113216. doi: 10.1016/j.jim.2022.113216. Epub 2022 Jan 7.
7
Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域突变的计算分析及其对抗体结合的影响
Viruses. 2022 Jan 30;14(2):295. doi: 10.3390/v14020295.
8
Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses and Inhibit Viral Replication .严重急性呼吸综合征冠状病毒 2 刺突蛋白新型表位诱导强烈的免疫反应并抑制病毒复制。
Front Immunol. 2021 Mar 26;12:613045. doi: 10.3389/fimmu.2021.613045. eCollection 2021.
9
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.一种针对严重急性呼吸综合征冠状病毒 2 刺突蛋白 RBD 的疫苗可诱导保护性免疫。
Nature. 2020 Oct;586(7830):572-577. doi: 10.1038/s41586-020-2599-8. Epub 2020 Jul 29.
10
Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.表位分析揭示了基于 SARS-CoV-2 RBD 的抗原中的关键抗原决定簇。
Front Immunol. 2021 Sep 21;12:707977. doi: 10.3389/fimmu.2021.707977. eCollection 2021.

本文引用的文献

1
The Impact of Mutations on the Pathogenic and Antigenic Activity of SARS-CoV-2 during the First Wave of the COVID-19 Pandemic: A Comprehensive Immunoinformatics Analysis.新冠疫情第一波期间突变对严重急性呼吸综合征冠状病毒2致病性和抗原活性的影响:一项全面的免疫信息学分析
Vaccines (Basel). 2021 Nov 30;9(12):1410. doi: 10.3390/vaccines9121410.
2
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.mRNA-1273 新冠疫苗有效性临床试验的免疫相关性分析。
Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23.
3
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗(BBV152)的有效性、安全性和批间免疫原性:一项随机、双盲、对照、3 期临床试验的中期结果。
Lancet. 2021 Dec 11;398(10317):2173-2184. doi: 10.1016/S0140-6736(21)02000-6. Epub 2021 Nov 11.
4
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性:一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
5
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.mRNA-1273 新型冠状病毒疫苗在盲法阶段完成时的效力。
N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22.
6
Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses.用于抗包膜RNA病毒疫苗的刺突蛋白修饰
Mol Biol. 2021;55(4):538-547. doi: 10.1134/S0026893321030158. Epub 2021 Aug 26.
7
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗(BBV152)的安全性和免疫原性:一项双盲、随机、1 期临床试验。
Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21.
8
Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.刺突蛋白在 Sars-CoV-2 疫苗设计中的结构域和功能。
Viruses. 2021 Jan 14;13(1):109. doi: 10.3390/v13010109.
9
Viral targets for vaccines against COVID-19.针对 COVID-19 的疫苗的病毒靶点。
Nat Rev Immunol. 2021 Feb;21(2):73-82. doi: 10.1038/s41577-020-00480-0. Epub 2020 Dec 18.
10
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗(阿斯利康)对 SARS-CoV-2 的安全性和有效性:巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.